Direct compression of Chuanbai Likang Powder Veterinary Grade API into tablets is initiated only after blendability data are generated from angle of repose, Hausner ratio, and bulk density measurements. A viable direct-compression window requires Hausner ratio below 1.25 and Carr’s compressibility index below 20%; if the powder fails these limits, dry granulation or wet granulation is introduced to reduce segregation. In a representative veterinary tablet matrix, the active ingredient is combined at 2% w/w to 25% w/w with microcrystalline cellulose 30% w/w to 65% w/w, sodium starch glycolate 2% w/w to 5% w/w, crospovidone 2% w/w to 5% w/w, and magnesium stearate 0.25% w/w to 0.75% w/w, using geometric dilution in 1:1 steps for the active fraction before high-shear dispersion. The final blend is mixed in a bin blender at 6 rpm to 12 rpm for 15 min to 30 min; blend uniformity samples drawn from 10 locations must meet Ph. Eur. 2.9.40 or USP ＜905＞ with acceptance value not exceeding 15 and relative standard deviation below 6% during process validation. Compression on a rotary press with 8 mm to 12 mm circular concave tooling and main compression force of 8 kN to 20 kN yields tablets with hardness of 50 N to 90 N; friability is assessed per USP ＜1216＞ and disintegration per USP ＜701＞ at 37 °C in phosphate buffer pH 6.8. The registered limits must be derived from pilot-batch data for the target species, and published data for this specific API is limited. Terminal products include oral veterinary tablets and livestock boluses that are dosed according to label claim and registered withdrawal period in the destination market.

Injectable Preparations Under Terminal Sterilisation and Aseptic Filling

In injectable processing, the limiting constraint is not tableting flow but apyrogenicity, sterility, and particulate matter control. Chuanbai Likang Powder is reconstituted or dissolved in Water for Injection complying with Ph. Eur. 2.2.5 and USP ＜1231＞; if the API is thermostable, terminal sterilisation at 121 °C for 15 minutes is applied after 0.22 µm filtration, while thermolabile actives require aseptic filtration and filling. A batch formula for an injectable solution may incorporate the API at 0.1% w/v to 10% w/v, sodium chloride 0.9% w/v for isotonicity, and pH adjustment with 0.1 M hydrochloric acid or sodium hydroxide to a target pH validated for the API; the finished solution is monitored for subvisible particles according to Ph. Eur. 2.9.19 and USP ＜788＞. Lyophilised powders for injection are produced by filtering the bulk solution, filling into depyrogenated vials under Grade A laminar flow, and lyophilising with a freezing ramp from 5 °C to -45 °C over 4 h, primary drying at -20 °C and 0.2 mbar, and secondary drying at 25 °C for 8 h; moisture in the freeze-dried cake is controlled below 2% by Karl Fischer titration. Endotoxin levels are measured per Ph. Eur. 2.6.14 and USP ＜85＞, with a veterinary injectable specification commonly not exceeding 0.5 EU/mg if an endotoxin limit is derived from the maximum daily dose. Published data on the exact lyophilisation cycle for this specific API is limited, so each protocol requires laboratory-scale freeze-drying microscopy before scale-up. Terminal finished products include injectable solutions or sterile powders for reconstitution intended for intramuscular or subcutaneous administration in cattle, swine, or companion animals.

In capsule filling, the limiting variables shift from dissolution to powder compressibility and particle-size distribution. Hard gelatin or hydroxypropyl methylcellulose capsules are filled with a preblend consisting of the API at 5% w/w to 30% w/w, lactose monohydrate or mannitol 50% w/w to 80% w/w, croscarmellose sodium 2% w/w to 5% w/w, and magnesium stearate 0.5% w/w; the lubricant is added only in the final 3 min to 5 min of mixing to avoid over-lubrication-induced dissolution slowdown. Fill weight is controlled gravimetrically every 15 min, targeting a fill-weight relative standard deviation below 3%; powder feed into the dosator or tamping-pin station requires bulk density above 0.40 g/cm³ for consistent slug formation. Content uniformity of capsule formulations is verified using Ph. Eur. 2.9.40 or USP ＜905＞, and dissolution testing follows Ph. Eur. 2.9.3 or USP ＜711＞ Apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid, although the registered dissolution medium is product-specific. Capsule shells must be selected for compatibility with the API’s hygroscopicity; if the API shows water uptake above 2% at 60% RH, desiccant packaging is required. Terminal finished products include companion-animal capsules and pre-weighed oral capsule doses for neonatal livestock, provided that capsule size is compatible with the target species’ oesophageal diameter.

What Water Activity Threshold Triggers Caking in Single-Use Powder Packs?

For oral water-soluble powders prepared from Chuanbai Likang Powder, the dominant failure mode is moisture-mediated caking rather than segregation. The powder blend for a finished water-soluble sachet is commonly composed of the API at 5% w/w to 20% w/w, anhydrous glucose or sucrose 70% w/w to 90% w/w, and colloidal silicon dioxide 0.5% w/w to 1% w/w; all filling operations are performed in an area maintained below 40% RH and 25 °C to keep water activity below 0.60, above which caking and loss of flow are observed in packaging trials. The dry blend is sifted through a 500 µm stainless-steel sieve and mixed in a tumble blender for 20 min; packaging into aluminium-foil or polyester-lined sachets is conducted under nitrogen purge if the API is oxygen-sensitive. Tests on the finished powder include loss on drying per Ph. Eur. 2.2.32 with a limit commonly set below 2%, and reconstitution time into 20 °C drinking water below 5 min to avoid dosing lag in medicated water systems. Terminal products are medicated drinking-water powders for poultry, swine, calves, and aquaculture species; the final drinking solution must be used within 24 h unless stability data support a longer use period. Published batch-specific water activity data for this configuration is limited.

During fluid-bed granulation of this veterinary API, the process variable that most strongly affects yield is inlet air temperature in relation to the binder solution glass transition. A binder such as povidone K30 is dissolved in purified water at 5% w/w to 10% w/w concentration and sprayed at 8 g/min to 15 g/min per kilogram of powder, while inlet air temperature is maintained between 50 °C and 70 °C and product temperature remains below 40 °C. The starting powder contains the API at 10% w/w to 30% w/w, microcrystalline cellulose 20% w/w to 40% w/w, lactose monohydrate 30% w/w to 60% w/w, and croscarmellose sodium 2% w/w to 5% w/w; granulation end point is determined by a moisture content of 3% to 5% and a granule size distribution of 250 µm to 850 µm for at least 80% of the mass. Dried granules are milled through a 1.0 mm screen and blended with magnesium stearate 0.5% w/w; final granules are assessed for sieve distribution per Ph. Eur. 2.9.12 and tapped density per Ph. Eur. 2.9.34. Terminal finished products include oral granules dosed via feed top-dressing for swine and cattle, and sachet granules reconstituted into a suspension for poultry or companion animals; dissolution testing follows Ph. Eur. 2.9.3 or USP ＜711＞ with the registered medium.

When Medicated Premix Carryover Must Stay Below Feed Mill Detection Limits

Manufacture of a medicated premix from Chuanbai Likang Powder shifts the critical control point from absolute API recovery to dilution homogeneity and cross-contamination carryover. Premix formulations are normally prepared at 1% w/w to 10% w/w active concentration on a carrier such as wheat bran, calcium carbonate, or ground corn cob; the carrier is pre-conditioned to moisture below 12% and sieved through a 1.0 mm screen to standardise particle-size distribution. Mixing is conducted in a horizontal ribbon blender at 15 rpm to 30 rpm for 10 min to 20 min, with sampling at 10 to 20 points; coefficient of variation below 5% is accepted under EU Regulation 2019/4 on medicated feed and Codex Alimentarius guidance for feed additive homogeneity, although the specific acceptance criterion is derived from the target dose in final feed. The premix is discharged into sealed bags and labelled with the recommended inclusion rate, commonly 0.1% to 2% in finished feed, so that the final medicated feed carries the therapeutic dose in the range defined by the marketing authorisation. Carryover is evaluated by measuring the active substance in the next non-medicated batch; if carryover exceeds 1% of the previous batch concentration, wash-out of the mixer with a coarse carrier is repeated. Terminal finished products include medicated feed premixes for swine, poultry, cattle, and fish feed mills, intended for mixing at registered feed mills rather than on-farm direct feeding.

Liquid Drench Manufacture Requires Viscosity Control Below the Filtration Cut-Off

Before liquid drench batches are compounded, the solubility envelope of Chuanbai Likang Powder is screened in aqueous buffers from pH 2.0 to 8.0; the selected buffer system is chosen to maintain the API at or above the labelled concentration without exceeding 600 mPa·s at 20 °C, above which filtration and filling lines show variable fill volume. A representative solution formula may contain the API at 0.5% w/v to 5% w/v, sodium benzoate 0.1% w/v or potassium sorbate 0.1% w/v, citric acid/disodium phosphate buffer 10 mM to 50 mM, and sorbitol 5% w/v to 15% w/v as a sweetener and cosolvent; the batch is mixed at 300 rpm to 600 rpm in a stainless-steel vessel without vortex formation to reduce air entrapment. Clarification uses a 0.45 µm polyethersulfone cartridge filter at a flux rate not exceeding 1 L/min per 0.1 m² of membrane; visible particles are checked against Ph. Eur. 2.9.20. Terminal products include oral drenches for cattle and sheep, poultry drinking-water concentrates, and calf bolus suspensions; stability of the solution is evaluated under VICH accelerated conditions at 40 °C and 75% RH for 6 months before storage condition claims are finalised. Specific solubility data for this API should be confirmed by phase-solubility analysis, and published data for this exact formulation is limited.